What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CTX310 is a lipid nanoparticle (LNP) formulation of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components for in vivo editing of the target gene angiopoietin-like 3 (ANGPTL3).”In the company’s words, NCT07491172 on ClinicalTrials.gov
- Tested for
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG) and 2 more
- Main trialPhase 1
- “This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.”In the company’s words, NCT07491172 on ClinicalTrials.gov
Other drugs for Cardiovascular
- ObicetrapibNewAmsterdam Pharma · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- OlezarsenIonis Pharmaceuticals, Inc. · Phase 3
- ResmetiromMadrigal Pharmaceuticals, Inc. · Phase 3
- SHR-1918Hengrui · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
Coming up1
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2027 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026